Escitalopram dose-response revisited: An alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression

International Journal of Neuropsychopharmacology

Volumn 7, Issue 3, 2004, Pages 283-290

  Bech, Per ^a   Tanghøj, Per ^b   Cialdella, Philippe ^a   Andersen, Henning Friis ^a   Pedersen, Anders Gersel ^b  

^a FREDERIKSBORG GENERAL HOSPITAL   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

Diagnostic instruments; Dose responsiveness; Major depression; Unidimensionality

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOMETRY; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; HYPNOTICS AND SEDATIVES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PYRIDINES; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP INITIATION AND MAINTENANCE DISORDERS; STEREOISOMERISM; SUICIDE;

EID: 4444257955     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004365     Document Type: Article

References (21)

1. Angst J, Scheidegger P, Stabl M (1993). Efficacy of moclobemide in different patient groups. Clinical Neuropharmacology 16 (Suppl. 2), 55-62.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th edn). Washington, DC: American Psychiatric Association.
3. Bech P (2001). Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. International Journal of Neuropsychopharmacology 4, 337-345.
4. Bech P (2002). Measurement issues. In: D'haenen H, den Boer JA, Willner P (Eds.), Biological Psychiatry, II (pp. 25-36). New York: John Wiley.
5. Bech P (In Press). Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs.
6. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, Nagy A (1981). The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica 63, 290-299.
7. Bech P, Cialdella P, Haugh M, Birkett MA, Hours A, Boissel JP, Tollefson GD (2000). A meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. British Journal of Psychiatry 176, 421-428.
8. Bech P, Tanghøj P, Andersen HF, Overø K (2002). Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology 163, 20-25.
9. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Journal of Clinical Psychiatry 63, 331-336.
10. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacological Bulletin 29, 321-326.
11. Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003). The problem of placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel design approach. Psychotherapy and Psychosomatics 72, 115-127.
12. Feighner JP, Overø K (1999). Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. Journal of Clinical Psychiatry 60, 824-830.
13. Guy W (1976). Clinical Global Impressions. Early Clinical Drug Evaluation Unit (ECDEU). ECDEU Assessment Manual for Psychopharmacology. Publication no. 76-338. Rockville: National Institute of Mental Health, 1976.
14. Hamilton M (1967). Development of a rating sale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
15. Hedges LV, Olkin I (1985). Statistical Methods for Meta-analysis. New York: Academic Press.
16. Mokken RJ (1971). A Theory and Procedure of Scale Analysis. Paris: Mouton.
17. Montgomery SA (1994). Clinically relevant effect sizes in depression. European Neuropsychopharmacology 4, 283-284.
18. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
19. Tignol J, Stoker MJ, Dunbar GC (1992). Paroxetine in the treatment of melancholia and severe depression. International Clinical Psychopharmacology 7, 91-94.
20. van der Heijden PG, van Buuren S, Fekkes M, Radder J, Verrips E (2003). Unidimensionality and reliability under Mokken scaling of the Dutch language version of the SF-36. Quality of Life Research 12, 189-198.
21. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D, Sertraline Pediatric Depression Study Group (2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Journal of the American Medical Association 290, 1033-1041.